RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo combo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new chemotherapy combination called CPX-351 in adults with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or hasn't responded to standard treatments. The main goals are to find the safest dose and under…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
New hope for tough blood cancers: stronger treatment before transplant
Disease control Recruiting nowThis study is testing a new, more intensive treatment plan for adults with aggressive blood cancers that are likely to return. The plan involves a combination of chemotherapy drugs and radiation, followed by a stem cell transplant from a donor. The goal is to see if this stronger…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new oral drug, seclidemstat, combined with an existing drug, azacitidine, for adults with certain advanced blood cancers (MDS and CMML) that have not responded well to prior treatment. The main goals are to find the safest and most effective dose of the ne…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough blood cancers: testing a Two-Pronged transplant attack
Disease control Recruiting nowThis study is testing a new approach to stem cell transplant for adults with aggressive blood cancers that have returned or not responded to treatment. The goal is to find the safest dose of radiation when combined with strong chemotherapy before the transplant, aiming to better …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New antibody injection tested to control rare blood cancers
Disease control Recruiting nowThis study is testing whether a medication called canakinumab, given as a monthly injection, can help control certain low-risk blood and bone marrow disorders. It aims to see if the treatment improves blood counts, reduces the need for blood transfusions, and is safe for patients…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New pill tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called onvansertib for people with rare, aggressive blood cancers that have come back or stopped responding to available treatments. The main goals are to find a safe dose and see if the drug can help control the disease. The stud…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo targets genetic flaws in tough blood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs, azacitidine and quizartinib, for adults with advanced forms of blood and bone marrow cancers (like myelodysplastic syndromes). The goal is to find the safest and most effective dose and see if the combination can help control thes…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Triple-Threat attack on tough blood cancers shows promise
Disease control Recruiting nowThis study is testing a new combination of three drugs—azacitidine, venetoclax, and gilteritinib—for adults with certain aggressive blood cancers that have returned or not responded to treatment. The main goals are to find the safest dose and see if adding gilteritinib helps pati…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New pill aims to turn immune system against tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Engineered immune cells target Leukemia's return
Disease control Recruiting nowThis early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC